These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 24901154)

  • 1. High-sensitivity C-reactive protein is a strong predictor of non-alcoholic fatty liver disease.
    Yeniova AO; Küçükazman M; Ata N; Dal K; Kefeli A; Başyiğit S; Aktaş B; Ağladioğlu K; Akin KO; Ertugrul DT; Nazligül Y; Beyan E
    Hepatogastroenterology; 2014; 61(130):422-5. PubMed ID: 24901154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients.
    Zimmermann E; Anty R; Tordjman J; Verrijken A; Gual P; Tran A; Iannelli A; Gugenheim J; Bedossa P; Francque S; Le Marchand-Brustel Y; Clement K; Van Gaal L; Sørensen TIA; Jess T
    J Hepatol; 2011 Sep; 55(3):660-665. PubMed ID: 21238518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-alcoholic fatty liver disease and its association with obesity, insulin resistance and increased serum levels of C-reactive protein in Hispanics.
    Riquelme A; Arrese M; Soza A; Morales A; Baudrand R; Pérez-Ayuso RM; González R; Alvarez M; Hernández V; García-Zattera MJ; Otarola F; Medina B; Rigotti A; Miquel JF; Marshall G; Nervi F
    Liver Int; 2009 Jan; 29(1):82-8. PubMed ID: 18647235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH.
    Yoneda M; Mawatari H; Fujita K; Iida H; Yonemitsu K; Kato S; Takahashi H; Kirikoshi H; Inamori M; Nozaki Y; Abe Y; Kubota K; Saito S; Iwasaki T; Terauchi Y; Togo S; Maeyama S; Nakajima A
    J Gastroenterol; 2007 Jul; 42(7):573-82. PubMed ID: 17653654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum intercellular adhesion molecule-1 in patients with nonalcoholic steatohepatitis: comparison with alcoholic hepatitis.
    Ito S; Yukawa T; Uetake S; Yamauchi M
    Alcohol Clin Exp Res; 2007 Jan; 31(1 Suppl):S83-7. PubMed ID: 17331172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [High-sensitivity C-reactive protein (hs-CRP): a promising biomarker for the screening of non-alcoholic steatohepatitis (NASH)].
    Uchihara M; Izumi N
    Nihon Rinsho; 2006 Jun; 64(6):1133-8. PubMed ID: 16768121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased Plasma Levels of Asymmetric Dimethylarginine in Nonalcoholic Fatty Liver Disease: Relation With Insulin Resistance, Inflammation, and Liver Histology.
    Boga S; Alkim H; Koksal AR; Bayram M; Ozguven MB; Ergun M; Neijmann ST; Ozgon G; Alkim C
    J Investig Med; 2015 Oct; 63(7):871-7. PubMed ID: 26244718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-normal levels of hs-CRP predict the development of non-alcoholic fatty liver in healthy men.
    Lee J; Yoon K; Ryu S; Chang Y; Kim HR
    PLoS One; 2017; 12(2):e0172666. PubMed ID: 28234943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of high sensitivity C-reaction protein in non-insulin dependent diabetes mellitus patients with non-alcoholic fatty liver disease.
    Bi Y; Min M; Shen W; Deng P; Du Q; Dong M; Liu Y
    Int J Clin Exp Pathol; 2015; 8(7):8494-9. PubMed ID: 26339423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Visceral adipose tissue and inflammation correlate with elevated liver tests in a cohort of overweight and obese patients.
    Verrijken A; Francque S; Mertens I; Talloen M; Peiffer F; Van Gaal L
    Int J Obes (Lond); 2010 May; 34(5):899-907. PubMed ID: 20142825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-alcoholic fatty liver disease is closely associated with sub-clinical inflammation: a case-control study on Asian Indians in North India.
    Nigam P; Bhatt SP; Misra A; Vaidya M; Dasgupta J; Chadha DS
    PLoS One; 2013; 8(1):e49286. PubMed ID: 23326306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).
    Verma S; Jensen D; Hart J; Mohanty SR
    Liver Int; 2013 Oct; 33(9):1398-405. PubMed ID: 23763360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma Pentraxin 3 Differentiates Nonalcoholic Steatohepatitis (NASH) from Non-NASH.
    Boga S; Koksal AR; Alkim H; Yilmaz Ozguven MB; Bayram M; Ergun M; Sisman G; Tekin Neijmann S; Alkim C
    Metab Syndr Relat Disord; 2015 Nov; 13(9):393-9. PubMed ID: 26367098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum inflammatory markers in overweight children and adolescents with non-alcoholic fatty liver disease.
    Neuman G; Sagi R; Shalitin S; Reif S
    Isr Med Assoc J; 2010 Jul; 12(7):410-5. PubMed ID: 20862821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of serum ferritin with non-alcoholic fatty liver disease: a meta-analysis.
    Du SX; Lu LL; Geng N; Victor DW; Chen LZ; Wang C; Yue HY; Xin YN; Xuan SY; Jin WW
    Lipids Health Dis; 2017 Dec; 16(1):228. PubMed ID: 29197393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel model using mean platelet volume and neutrophil to lymphocyte ratio as a marker of nonalcoholic steatohepatitis in NAFLD patients: multicentric study.
    Abdel-Razik A; Mousa N; Shabana W; Refaey M; ElMahdy Y; Elhelaly R; Elzehery R; Zalata K; Arafa M; Elbaz S; Hafez M; Awad M
    Eur J Gastroenterol Hepatol; 2016 Jan; 28(1):e1-9. PubMed ID: 26469357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased risk for development of coronary artery calcification in subjects with non-alcoholic fatty liver disease and systemic inflammation.
    Kim J; Lee DY; Park SE; Park CY; Lee WY; Oh KW; Park SW; Rhee EJ
    PLoS One; 2017; 12(7):e0180118. PubMed ID: 28686633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Assessment of high sensitivity C-reactive protein (HS-CRP) as a marker of liver inflammation in patients with metabolic syndrome].
    Rodríguez-Leal GA; Morán S; Gallardo I; Milke P; Guevara-González L
    Rev Gastroenterol Mex; 2006; 71(1):39-45. PubMed ID: 17063573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High sensitive CRP and pentraxine 3 as noninvasive biomarkers of nonalcoholic fatty liver disease.
    Maleki I; Rastgar A; Hosseini V; Taghvaei T; Rafiei A; Barzin M; Torabizadeh Z; Naghshvar F; Khalilian A
    Eur Rev Med Pharmacol Sci; 2014 Jun; 18(11):1583-90. PubMed ID: 24943967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum procalcitonin and CRP levels in non-alcoholic fatty liver disease: a case control study.
    Oruc N; Ozutemiz O; Yuce G; Akarca US; Ersoz G; Gunsar F; Batur Y
    BMC Gastroenterol; 2009 Feb; 9():16. PubMed ID: 19222849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.